本文選題：阿托伐他汀 + 缺血性腦血管病�。� 參考：《中國實用神經(jīng)疾病雜志》2016年23期

【摘要】：目的探討不同劑量阿托伐他汀對缺血性腦血管病患者臨床生化指標的影響。方法采用隨機雙盲對照方法,收集我院100例缺血性腦血管患者,隨機分成2組,實驗組(50例)在常規(guī)治療缺血性腦血管病基礎上給予阿托伐他汀40mg/d治療,對照組(50例)在常規(guī)治療缺血性腦血管病基礎上給予阿托伐他汀20mg/d治療,療程均為3個月。檢測并對比2組治療前后臨床生化指標。結(jié)果 2組三酰甘油(TG)、膽固醇(TC)、低密度脂蛋白膽固醇(LDL-C)、同型半胱氨酸(Hcy)、C反應蛋白(CRP)水平與治療前比較均顯著下降(P0.05);同時,2組高密度脂蛋白膽固醇(HDL-C)與治療前比較明顯升高(P0.05)。實驗組空腹血糖(FBS)、糖化血紅蛋白(HbA1c)水平與治療前比較明顯升高(P0.05),對照組無明顯變化(P0.05)。結(jié)論不同劑量的阿托伐他汀治療3個月后均能有效改善血脂水平,而高劑量(40mg/d)阿托伐他汀可能導致血糖異常,低劑量(20mg/d)阿托伐他汀對患者血糖升高無影響,對于缺血性腦血管病患者采用低劑量阿托伐他汀治療更安全有效。
[Abstract]:Objective to investigate the effects of different doses of Atto vastatin on clinical biochemical indexes in patients with ischemic cerebrovascular disease. Methods 100 patients with ischemic cerebrovascular diseases in our hospital were randomly divided into two groups, the experimental group (n = 50) and the control group (n = 50). Atto vastatin 40mg/d was given on the basis of routine treatment of ischemic cerebrovascular disease. The control group (n = 50) was treated with Atto vastatin 20mg/d for 3 months on the basis of routine treatment of ischemic cerebrovascular disease. The clinical biochemical indexes before and after treatment were detected and compared between the two groups. Results the levels of TGG, TC, LDL-CU, Hcysteine C reactive protein (CRP) in the two groups were significantly decreased compared with those before treatment, and HDL-C in the two groups were significantly increased compared with those before treatment (P 0.05), and the levels of HDL-C in the two groups were significantly higher than those in the control group (P < 0.05), while the levels of HDL-C in the two groups were significantly higher than those in the control group (P < 0.05). The levels of FBSN, HbA1c) in the experimental group were significantly higher than those before treatment, but there was no significant change in the control group. Conclusion different doses of Atto vastatin can effectively improve blood lipid level after 3 months of treatment, while high dose of 40 mg / d) Atto vastatin may lead to abnormal blood glucose. Low dose of 20 mg / d Atto vastatin has no effect on the increase of blood glucose in patients. It is more safe and effective to treat ischemic cerebrovascular disease with low dose Atto vastatin.
【作者單位】： 重慶三峽中心醫(yī)院神經(jīng)內(nèi)科;
【分類號】：R743.3
，

本文編號：1859772